The CEO's $1.11M open-market purchase at $11.12 is a material vote of confidence from the top executive, especially given the stock's 86% analyst buy rating. The CLO's $398K sale is small and likely routine portfolio management. Traders should watch for upcoming clinical catalysts or partnership announcements that may have motivated the CEO's buy. The historical win rate on KURA long calls is 71% at T+20, supporting a bullish read.
Price Chart
Executive Summary
Kura Oncology CEO Troy Wilson purchased $1.11M of stock on the open market at $11.12/share, while Chief Legal Officer Teresa Brophy sold $398K at $12.63. The CEO's large open-market buy is a strong bullish signal, especially given the company's $1.0B market cap, while the CLO's sale is routine in size and likely liquidity-driven. The net direction is mixed by count but heavily skewed to buying by dollar value and insider seniority.
Key Financial Metrics
Key Facts
- CEO Troy Wilson purchased 100,000 shares for $1.11M at $11.12 on 2026-08-17
- CLO Teresa Brophy sold 31,487 shares for $398K at $12.63 on 2026-08-19
- CEO buy represents ~0.11% of KURA's $1.0B market cap
- CLO sale represents ~0.04% of market cap
- Net insider dollar flow is +$714K (buying dominates by 2.8x)
- 86% of analysts rate the stock Buy or Strong Buy
Financial Impact
CEO invested $1.11M of personal capital at $11.12/share, representing ~0.11% of market cap; CLO sale of $398K is routine
Risk Factors
- CLO sale creates a mixed signal that may confuse some traders
- Biotech stocks are binary — CEO buying does not guarantee clinical trial success
- Stock has high volatility (recent T+5 moves of -15% to +16%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KURA-1787378817615 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access